BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine

From National Research Council Canada

Download
  1. (PDF, 4.2 MiB)
  2. (PDF, 1.3 MiB)
  3. (DOCX, 30 KiB)
DOIResolve DOI: https://doi.org/10.1016/j.isci.2023.107612
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: 1; Search for: 1; Search for: ; Search for: ; Search for: ; Search for: 1; Search for: ; Search for: 1; Search for: ; Search for: ; Search for: ; Search for: ORCID identifier: https://orcid.org/0000-0002-9012-4212
Affiliation
  1. National Research Council of Canada. Human Health Therapeutics
FormatText, Article
Abstract
Publication date
PublisherElsevier
Licence
In
LanguageEnglish
Peer reviewedYes
IdentifierS2589004223016899
Export citationExport as RIS
Report a correctionReport a correction (opens in a new tab)
Record identifierf92e42df-d0b5-43cd-bd76-cec099f899ec
Record created2024-05-28
Record modified2024-05-28
Date modified: